It is produced by the strain of Actinomadura paroosalo. It's a glycopeptide antibiotic. It has inhibitory effect on Staphylococcus aureus, Staphylococcus furfur, Staphylococcus hemolyticus and enterococcus faecalis. Parvodicin C1 and C2 have stronger antibacterial effects than Parvodicin C3 and C4. The antibacterial activity of Parvodicin C is 1-4 times stronger than Tecomycin and 2-4 times stronger than vancomycin. The terminal branching activity of lipid chains is greater than straight chains (C1>C2>C3>C4, B1>B2), and the chain length is greater than short chains (C2>B). The half-life of Parvodicin C1 is longer in vivo than vancomycin and Archeomycin.